hTERT-molecular targeted therapy of ovarian cancer cells via folate-functionalized PLGA nanoparticles co-loaded with MNPs/siRNA/wortmannin

Life Sciences ◽  
2021 ◽  
pp. 119621
Author(s):  
Somayyeh Ghareghomi ◽  
Shahin Ahmadian ◽  
Nosratollah Zarghami ◽  
Salar Hemmati
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapy ◽  
Cancer Cells ◽  
Molecular Targeted Therapy ◽  
Plga Nanoparticles ◽  
Ovarian Cancer Cells

Abstract 4467: Differential response of ERa-targeted therapy in breast and ovarian cancer cells by 17b-estradiol-linked platinum(II) hybrid (E2-Pt(II)), VP-128

2010 ◽  
Author(s):  
Sophie Parent ◽  
Céline Van Themsche ◽  
Valérie Leblanc ◽  
Caroline Descôteaux ◽  
Josée Provencher-Mandeville ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapy ◽  
Cancer Cells ◽  
Differential Response ◽  
Ovarian Cancer Cells ◽  
Breast And Ovarian Cancer

PLGA-nanoparticles loaded with a thiosemicarbazone derived palladium(ii) complex as a potential agent to new formulations for human ovarian carcinoma treatment

2020 ◽  
Vol 44 (35) ◽  
pp. 14928-14935
Author(s):  
Carolina G. Oliveira ◽  
Luciana F. Dalmolin ◽  
R. T. C. Silva ◽  
Renata F. V. Lopez ◽  
Pedro I. S. Maia ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Viability ◽  
Ovarian Carcinoma ◽  
Cancer Cells ◽  
Plga Nanoparticles ◽  
Cytotoxic Agent ◽  
Ovarian Cancer Cells ◽  
Ovarian Cell ◽  
Encapsulation Process ◽  
Human Ovarian Carcinoma

The encapsulation process of the PdII complex [PdCl(PPh3)(PrCh)], a promising cytotoxic agent on ovarian cancer cells, in PLGA polymer was studied. The cytotoxicity results showed that the formulation led to a significant reduction of the ovarian cell viability (80% at 1 μM).

AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells

Nanomedicine ◽  
2018 ◽  
Vol 13 (21) ◽  
pp. 2729-2758 ◽  
Author(s):  
Somayeh Vandghanooni ◽  
Morteza Eskandani ◽  
Jaleh Barar ◽  
Yadollah Omidi
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapy ◽  
Cancer Cells ◽  
Glycolic Acid ◽  
Ovarian Cancer Cells ◽  
As1411 Aptamer

Abstract 2516: ERa-targeted therapy in ovarian cancer cells by 17b-estradiol-linked chemotherapeutic hybrid; VP-128 (E2-Pt(II))

2011 ◽  
Author(s):  
Kevin Brasseur ◽  
Valérie Leblanc ◽  
Sophie Parent ◽  
Caroline Descôteaux ◽  
Gervais Bérubé ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapy ◽  
Cancer Cells ◽  
Ovarian Cancer Cells

Abstract 4889: ERa-targeted therapy in ovarian cancer cells using novel Estradiol-Platinum(II) hybrids

2012 ◽  
Author(s):  
Kevin Brasseur ◽  
Valérie Leblanc ◽  
Céline Van Themsche ◽  
Sophie Parent ◽  
Caroline Descoteaux ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Targeted Therapy ◽  
Cancer Cells ◽  
Ovarian Cancer Cells

scholarly journals PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment

Pharmaceutics ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 439 ◽  
Author(s):  
Ana I. Fraguas-Sánchez ◽  
Ana I. Torres-Suárez ◽  
Marie Cohen ◽  
Florence Delie ◽  
Daniel Bastida-Ruiz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Treatment ◽  
Cancer Cells ◽  
Intraperitoneal Administration ◽  
Spherical Shape ◽  
Plga Nanoparticles ◽  
Ovarian Cancer Cells ◽  
In Ovo ◽  
Anticancer Efficacy

The intraperitoneal administration of chemotherapeutics has emerged as a potential route in ovarian cancer treatment. Nanoparticles as carriers for these agents could be interesting by increasing the retention of chemotherapeutics within the peritoneal cavity. Moreover, nanoparticles could be internalised by cancer cells and let the drug release near the biological target, which could increase the anticancer efficacy. Cannabidiol (CBD), the main nonpsychotropic cannabinoid, appears as a potential anticancer drug. The aim of this work was to develop polymer nanoparticles as CBD carriers capable of being internalised by ovarian cancer cells. The drug-loaded nanoparticles (CBD-NPs) exhibited a spherical shape, a particle size around 240 nm and a negative zeta potential (−16.6 ± 1.2 mV). The encapsulation efficiency was high, with values above 95%. A controlled CBD release for 96 h was achieved. Nanoparticle internalisation in SKOV-3 epithelial ovarian cancer cells mainly occurred between 2 and 4 h of incubation. CBD antiproliferative activity in ovarian cancer cells was preserved after encapsulation. In fact, CBD-NPs showed a lower IC50 values than CBD in solution. Both CBD in solution and CBD-NPs induced the expression of PARP, indicating the onset of apoptosis. In SKOV-3-derived tumours formed in the chick embryo model, a slightly higher—although not statistically significant—tumour growth inhibition was observed with CBD-NPs compared to CBD in solution. To sum up, poly-lactic-co-glycolic acid (PLGA) nanoparticles could be a good strategy to deliver CBD intraperitoneally for ovarian cancer treatment.

Cytotoxic effects of disulfiram and synergism with cisplatin on ovarian cancer cells in vitro

2018 ◽  
Author(s):  
F Guo ◽  
Z Yang ◽  
J Xu ◽  
J Sehouli ◽  
AE Albers ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Cytotoxic Effects
Sign in / Sign up

Export Citation Format

Share Document